Jill Beraud - May 1, 2024 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role
Director
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Stock symbol
RVNC
Transactions as of
May 1, 2024
Transactions value $
$0
Form type
4
Date filed
5/3/2024, 08:42 AM
Previous filing
Apr 26, 2024
Next filing
May 28, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Award $0 +15K +52.44% $0.00 43.6K May 1, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVNC Stock Option (Right to buy) Award $0 +23.5K $0.00 23.5K May 1, 2024 Common Stock 23.5K $3.80 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an annual restricted stock award (the "RSA") granted pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan (the "Plan")) through such vesting date.
F2 The shares subject to the stock option shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy.